Febrile Neutropenia Clinical Trial
Official title:
Efficacy of Extended Infusion of β-lactam Antibiotics for the Treatment of Febrile Neutropenia in Haematologic Patients: a Randomised, Multicentre, Open-label, Superiority Clinical Trial (BEATLE)
This study evaluates the administration of beta-lactam antibiotics in extended infusion in hematological patients with febrile neutropenia after 5 days of treatment. The beta-lactam antibiotics analyzed are the following: piperacillin-tazobactam, cefepime and meropenem. Half of patients will receive the antibiotic in intermittent infusion, while the other half will receive it in extended infusion.
Febrile neutropenia (FN) is a very frequent complication in patients with hematological malignancies. It is associated with an important morbidity and mortality. Nowadays the use of betalactam antibiotics (BLA) in extended or continuous infusion (EI, CI) instead of intermittent infusion (II), has demonstrated a therapeutic success and lower mortality rate in critically ill intensive care patients. Neutropenic patients are a particular population since FN is assoicated with pathophysiological variations that compromise pharmacokinetic parameters of BLA, and may therefore, diminish their clinical efficacy. Information regarding the usefulness of BLA in EI in neutropenic hematologic patients is scarce. The objective of this randomized clinical trial is to demonstrate the clinical superiority of the administration of BLA in EI compared to II in patients with FN. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03641131 -
Ampholipad Real-World Data in Taiwan
|
||
| Not yet recruiting |
NCT02806557 -
Profiling Neutrophil Counts in Patients on Chemotherapy
|
N/A | |
| Completed |
NCT04914702 -
Feasibility and Comparison of Continuously Monitored Vital Signs in Pediatric Patients With Cancer.
|
||
| Completed |
NCT02728596 -
S1415CD, Trial Assessing CSF Prescribing Effectiveness and Risk (TrACER)
|
N/A | |
| Completed |
NCT03104595 -
Management of Severe Chemotherapy-induced Neutropenia in Advanced Breast Cancer
|
Phase 1/Phase 2 | |
| Recruiting |
NCT02536599 -
Risk Factors & Outcomes for Clinically Documented Infections in Pediatric Cancer Patients With Fever & Neutropenia
|
||
| Completed |
NCT02005783 -
Study of Danggui Buxue Decoction in Preventing Neutropenia
|
Phase 2 | |
| Recruiting |
NCT03449693 -
Efficacy of Oral Supplementation With Magnesium to Reduce Febrile Neutropenia
|
Phase 2 | |
| Recruiting |
NCT05149547 -
mNGS Versus Blood Culture in FN
|
||
| Recruiting |
NCT05584930 -
Clusterin, Ptx3 and Pediatric Febrile Neutropenia (CluPPFeN)
|
N/A | |
| Completed |
NCT04134429 -
Feasibility of Monitoring Health Data in Pediatric Patients Undergoing Chemotherapy
|
||
| Recruiting |
NCT01684189 -
Registry of Febrile Neutropenia and Invasive Fungal Infections
|
N/A | |
| Completed |
NCT00462878 -
Meropenem Versus Meropenem Plus Glycopeptide in Patients With Febrile Neutropenia After Allogenic Blood Stem Cell Transplantation
|
N/A | |
| Completed |
NCT00035425 -
Treatment of Neutropenic Patients With Fever Who Are Suspected to Have A Gram Positive Infection
|
Phase 3 | |
| Recruiting |
NCT04948463 -
Early Versus Late Stopping of Antibiotics in Children With Cancer and High-risk Febrile Neutropenia
|
Phase 4 | |
| Recruiting |
NCT03740464 -
Long-acting G-CSF for Febrile Neutropenia
|
Phase 3 | |
| Not yet recruiting |
NCT06116734 -
Lapelga vs Gastrofil
|
Phase 3 | |
| Completed |
NCT00503854 -
Fatigue and Symptom Burden in Low-Risk Cancer Patients Undergoing Treatment for Febrile Neutropenia
|
||
| Terminated |
NCT02732327 -
Comparative Study of Ceftazidime-Avibactam Versus Standard of Care as Therapy in Febrile Neutropenic Adults With Cancer
|
Phase 2 | |
| Completed |
NCT01114165 -
Value of the LightCycler® SeptiFast Test MGRADE for the Pathogen Detection in Neutropenic Hematological Patients
|
Phase 4 |